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The serine/threonine kinase Akt, also known as protein kinase B (PKB), is a central node in cell 
signaling downstream of growth factors, cytokines, and other cellular stimuli. Aberrant loss 
or gain of Akt activation underlies the pathophysiological properties of a variety of complex 
diseases, including type-2 diabetes and cancer. Here, we review the molecular properties of 
Akt and the approaches used to characterize its true cellular targets. In addition, we discuss 
those Akt substrates that are most likely to contribute to the diverse cellular roles of Akt, 
which include cell survival, growth, proliferation, angiogenesis, metabolism, and migration.The serine/threonine kinase Akt/PKB has emerged as a 
critical signaling node within all cells of higher eukaryotes 
and as one of the most important and versatile protein 
kinases at the core of human physiology and disease. 
Since its discovery as an oncogene within the mouse 
leukemia virus AKT8 (Bellacosa et al., 1991; Staal, 1987) 
and as a homolog of protein kinase C (Jones et al., 1991), 
there have been many exciting breakthroughs elucidat-ing the mechanism of upstream regulation of Akt (sum-
marized in Figure 1). Several excellent recent reviews 
have covered the molecular details of Akt regulation 
and its role in human disease (such as Bellacosa et al., 
2005; Engelman et al., 2006). Here, we focus on sign-
aling downstream of Akt, with an emphasis on direct 
phosphorylation targets of the kinase and its bona fide 
cellular functions.Figure 1. Upstream Activation of Akt by 
Growth Factors
Also depicted is the complex relationship be-
tween Akt signaling and mTOR. Activated re-
ceptor tyrosine kinases (RTKs) activate class I 
phosphatidylinositol 3-kinase (PI3K) through di-
rect binding or through tyrosine phosphorylation 
of scaffolding adaptors, such as IRS1, which 
then bind and activate PI3K. PI3K phosphor-
ylates phosphatidylinositol-4,5-bisphosphate 
(PIP2) to generate phosphatidylinositol-3,4,5-tri-
sphosphate (PIP3), in a reaction that can be re-
versed by the PIP3 phosphatase PTEN. AKT and 
PDK1 bind to PIP3 at the plasma membrane, 
and PDK1 phosphorylates the activation loop 
of AKT at T308. RTK signaling also activates 
mTOR complex 2 (mTORC2) through a currently 
unknown mechanism, and mTORC2 phosphor-
ylates Akt on the hydrophobic motif S473, which 
can be dephosphorylated by the S473 phos-
phatase PHLPP. Akt activates mTOR complex 1 
(mTORC1) through multisite phosphorylation of 
TSC2 within the TSC1-TSC2 complex, and this 
blocks the ability of TSC2 to act as a GTPase-ac-
tivating protein (GAP) for Rheb, thereby allowing 
Rheb-GTP to accumulate. Rheb-GTP activates 
mTORC1, which phosphorylates downstream 
targets such as 4E-BP1 and the hydrophobic 
motif on the S6 kinases (S6Ks; T389 on S6K1). 
PDK1 phosphorylates the activation loop on the S6Ks (T229 on S6K1) in a reaction independent of PDK1 binding to PIP3. Akt can also activate 
mTORC1 by phosphorylating PRAS40, thereby relieving the PRAS40-mediated inhibition of mTORC1. Once active, both mTORC1 and S6K can 
phosphorylate serine residues on IRS1, which targets IRS1 for degradation, and this serves as a negative feedback mechanism to attenuate PI3K-
Akt signaling. See text for references to recent reviews detailing Akt regulation and mTOR signaling.Cell 129, June 29, 2007 ©2007 Elsevier Inc. 1261
Substrate Specificity
The three Akt isoforms (Akt1/PKBα, Akt2/PKBβ, and 
Akt3/PKBγ) have extensive homology to protein kinases 
A, G, and C within their kinase domains and are, there-
fore, members of the AGC kinase family. Following the 
identification of a residue on the kinase GSK3 as the first 
direct target of Akt in cells (Cross et al., 1995), ground-
breaking experiments with peptides containing vari-
ants of this sequence defined the minimal recognition 
motif of Akt as R-X-R-X-X-S/T-B (Alessi et al., 1996b), 
where X represents any amino acid and B represents 
bulky hydrophobic residues. The critical requirement for 
R residues at both the −5 and −3 positions (that is, 5 
and 3 residues, respectively, N-terminal to the phospho-
acceptor site) on peptides efficiently phosphorylated by 
Akt distinguishes the substrate specificity of Akt from 
that of two other mitogen-stimulated AGC kinases, RSK 
(MAPKAP-K1) and S6K1 (p70S6K), which can better tol-
erate K at these positions. In these “peptide-bashing” 
experiments, more subtle Akt preferences were also 
uncovered for other residues surrounding the phospho-
rylation site (such as a preference for T at −2). Struc-
tural insights into the molecular interactions dictating 
the substrate selectivity of Akt have been provided by 
a high-resolution crystal structure of Akt bound to this 
GSK3 peptide substrate (Yang et al., 2002).
Further details of the preferred substrate specificity of 
Akt have been obtained using peptide library screening 
(Hutti et al., 2004; Obata et al., 2000), which provides an 
unbiased, systematic, and quantitative score for all 20 
amino acids at each site within seven residues N-termi-
nal and C-terminal to the phospho-acceptor site. This 
approach allows the identification of residues selected 
both for and against by the kinase of interest at each 
position surrounding the phosphorylation site. A bioinfor-
matics program called Scansite (http://scansite.mit.edu; 
Yaffe et al., 2001) has provided the ability to search pro-
tein databases with the matrix of data obtained from such 
screens, rather than a single consensus sequence, and 
has been instrumental in identifying new Akt substrates 
and narrowing down target residues on suspected sub-
strates. However, this approach needs to be used with 
caution, as it is only useful for identifying candidate phos-
phorylation sites. The sheer number of high-quality Akt 
sites within the proteome, in addition to the overlap in 
substrate specificity with other AGC kinases, illustrates 
the need for a rigorous demonstration of the direct in vivo 
phosphorylation of a given candidate target by Akt.
It remains possible that there are unknown sequence 
contexts or macromolecular interactions within cells that 
might allow Akt to phosphorylate motifs other than the 
minimally required R-X-R-X-X-S/T. Currently, however, 
there are no rigorously demonstrated and independ-
ently confirmed Akt substrates that fall into this cat-
egory. Therefore, in the discussion of substrate charac-
terization and the role of specific substrates below, we 
consider the presence of an R-X-R-X-X-S/T motif to be 
essential.1262 Cell 129, June 29, 2007 ©2007 Elsevier Inc.Defining Criteria for Bona Fide Akt Substrates
Here we review criteria that, in our view, should be met 
to define an in vivo Akt substrate. We recognize the limits 
of such standards, as it is possible that the same site 
phosphorylated by Akt in one cell type under one condi-
tion might be phosphorylated by additional kinases in 
other settings. However, given the increasing complexity 
of Akt signaling and its importance in human physiol-
ogy and disease, it is worth evaluating the experimental 
paradigms currently used to define a direct downstream 
target of Akt. Our discussion is specific to Akt, but the 
criteria are similar to that put forward for other protein 
kinases (Frame and Cohen, 2001). Many approaches 
have been used to demonstrate phosphorylation of 
sites on target proteins within cells. However, no single 
method is sufficient; rather, both Akt loss- and gain-of-
function approaches are needed. In the end, it is essen-
tial to demonstrate that phosphorylation of a candidate 
site on an endogenous substrate is induced by specific 
physiological stimuli that activate endogenous Akt and 
that the phosphorylation is lost upon Akt inactivation.
In Vitro Phosphorylation
Demonstration of direct in vitro phosphorylation of a 
candidate R-X-R-X-X-S/T site by Akt is a necessary step 
in defining an Akt substrate. Phosphorylation of the full-
length protein of interest should be demonstrated, rather 
than fragments or motifs fused to other proteins (e.g., 
GST). Phosphate incorporation at the relevant site must 
be demonstrated. However, Akt is a somewhat promis-
cuous kinase in vitro and will phosphorylate most R-X-R-
X-X-S/T sites and some R-X-X-S/T sites if given enough 
time and substrate. Therefore, in vitro phosphorylation, 
although necessary, is not sufficient for defining a new 
phosphorylation site for Akt.
Phosphorylation-Site Readout
In order to confirm candidate phosphorylation sites 
detected using bioinformatics and/or in vitro approaches, 
one first needs a reliable and specific readout of the 
phosphorylation event in question. This can occasion-
ally be detected as a shift to a slower migrating form 
on denaturing polyacrylamide gels. However, it is rare 
that phosphorylation of an Akt site causes such a shift, 
which is usually indicative of a proline-directed site (i.e., 
S/T-P), and Akt poorly phosphorylates such sites (Alessi 
et al., 1996b; Hutti et al., 2004). Mass spectrometry 
techniques and in vivo [32P]-orthophosphate labeling fol-
lowed by two-dimensional phospho-peptide mapping 
are indispensable tools for identifying in vivo phosphor-
ylation sites. However, due to their time-consuming and 
low-throughput nature, these approaches are somewhat 
less useful as an experimental readout when character-
izing cellular conditions and kinases responsible for the 
phosphorylation. Antibodies specific for a phosphor-
ylated motif (i.e., phospho-substrate antibodies) have 
been extremely valuable for identifying and character-
izing new Akt substrates over the past five years (e.g., 
Kovacina et al., 2003; Manning et al., 2002; Sano et al., 
2003). These antibodies are raised against degenerate 
phospho-peptides containing the phosphorylated mini-
mal Akt substrate motif (R-X-R-X-X-pS/pT; Zhang et al., 
2002). Although these antibodies are helpful in identify-
ing candidate Akt sites, mutation analysis must be used 
to confirm that the antibody is recognizing the predicted 
site(s). As a cautionary note, at least some of the cur-
rently available Akt phospho-substrate antibodies can 
recognize R-X-X-pS/pT motifs in sequence contexts 
lacking an R at the −5 position (Zhang et al., 2002), and 
this is especially true when such a phospho-protein is 
overexpressed (B.D.M., unpublished data). Finally, once 
data are obtained suggesting the regulated phosphor-
ylation of a specific site, the gold standard is the use of a 
phospho-specific antibody unique to the site of interest. 
Regardless of the readout for a given phosphorylation 
event, this approach must be followed by experiments 
that demonstrate a requirement for Akt.
Pharmacological
The growth-factor-stimulated phosphorylation of an Akt 
site should be sensitive to pretreatment with phosphati-
dylinositol 3-kinase (PI3K) inhibitors, such as wortman-
nin (≤100 nM) or LY294002 (≤20 µM), as class I PI3Ks 
are upstream activators of Akt (Figure 1). Although a 
low dose of wortmannin is specific to PI3K, it inhibits all 
classes of PI3Ks, and there are likely to be PI3K-regu-
lated kinases, other than Akt, that are affected by such 
inhibition. Resistance to highly specific inhibitors of the 
kinases RSK (e.g., BI-D1870; Sapkota et al., 2007) and 
mTORC1 (e.g., rapamycin) is also important for ruling 
out RSK and S6K, respectively, as candidate kinases 
for the in vivo phosphorylation event observed. Specifi-
city issues exist with currently available Akt inhibitors, 
thereby limiting their use for defining Akt as the relevant 
kinase for a given phosphorylation event or cellular 
function. However, inhibitors that target regions of Akt 
outside of its highly conserved ATP-binding pocket are 
promising and should show increased specificity for Akt 
over other AGC kinases. As the specificity of AGC kinase 
inhibitors improves, they will certainly be valuable tools 
in identifying and verifying Akt substrates.
Loss of Function
The current limitations of pharmacological approaches 
dictate that Akt-specific loss-of-function approaches 
are needed. Although recently developed cell lines lack-
ing Akt function provide the most stringent setting for 
confirming a substrate (see below), several types of 
dominant-negative Akt constructs are available, with 
variable success at inhibiting endogenous Akt. In our 
experience, Akt lacking its two activating phosphoryla-
tion sites (Akt-T308A/S473A) works more reproducibly 
as a dominant-negative than the kinase-dead (K179D) 
version. However, the molecular mechanisms underly-
ing the dominant-negative effects of these various con-
structs are unknown, and potential effects on upstream 
kinases such as phosphoinositide-dependent kinase-1 
(PDK1) and mTORC2 make this approach less desira-
ble. Knockdown of Akt isoforms through small interfer-
ing (si)RNAs is becoming used more often to define Akt substrates and functions. Knowledge of the expression 
patterns of different Akt isoforms and the use of iso-
form-specific antibodies are important considerations 
here. It is likely that, in any given setting, knockdown of 
more than one isoform will be required. However, recent 
studies suggest that isoform-specific substrates and 
functions of Akt are more common than previously sus-
pected (see below).
Gain of Function
Overexpression of exogenous Akt constructs invariably 
increases the basal and stimulated phosphorylation of 
its substrates. However, given the strict temporal and 
spatial regulation that accompany kinase-substrate 
interactions in cells, exogenously overexpressed con-
structs should never be used as the sole basis for defin-
ing an Akt substrate. Membrane-targeting versions of 
Akt, such as myristoylated PH domain-deleted Akt (myr-
∆PH-Akt)—which are brought to the plasma membrane 
independent of PI3K activity—have been the most widely 
used for determining the cellular effects of constitutive 
activation of Akt (Andjelkovic et al., 1997; Kohn et al., 
1996). However, depending on the membrane-target-
ing construct used, differential effects on downstream 
signaling can be detected. An alternative is the phos-
pho-mimetic mutant of Akt (Akt-T308D/S473D), which 
has lower activity than the myr-Akt derivatives but is 
constitutively active and PI3K independent (Alessi et al., 
1996a). Overall, the general concerns regarding poten-
tial overexpression artifacts definitely apply to kinase-
substrate interactions and phosphorylation events, and 
results obtained with such constructs should be inter-
preted with caution.
Genetics
Genetic systems have been instrumental in identify-
ing and confirming kinase substrates. C. elegans and 
Drosophila genetics have been powerful tools for elu-
cidating signaling pathways. An important example of 
using a genetic approach to elucidate Akt signaling 
was the finding that the forkhead box O (FOXO) tran-
scription factor Daf-16 is downstream of the PI3K and 
Akt orthologs in C. elegans for control of the devel-
opmental and metabolic state referred to as dauer 
(Paradis and Ruvkun, 1998). Although genetic epista-
sis analysis is useful for positioning new candidate 
substrates downstream of a specific kinase and for 
functional insights into the effects of a kinase on the 
given target, more rigorous approaches are needed to 
demonstrate a direct phosphorylation. However, loss-
of-function or deletion alleles of a kinase can be valu-
able for confirming the kinase specificity of an in vivo 
phosphorylation event. To this end, mouse genetic 
models have been increasingly important for defining 
bona fide targets of Akt. A variety of isoform-specific 
Akt knockout mice and combinations have now been 
made (reviewed in Dummler and Hemmings, 2007), 
and these can be used to demonstrate that phospho-
rylation of a given substrate requires a specific Akt 
isoform in a particular cell type of interest. Other pow-Cell 129, June 29, 2007 ©2007 Elsevier Inc. 1263
Table 1. Characteristics and Experimental Evidence for a Subset of Akt Substratesa
Target Human Site(s)b In Vitroc
In Vivod
Genetic Evidencee Regulatory Effect?fW/L LOF GOF
FOXO1 T24, S256, S319 + + + + M, F, W Inhibit
FOXO3A T32, S253, S315 + + + + M, F, W Inhibit
FOXO4 T32, S197, S262 + + + + M, F, W Inhibit
TSC2 S939, T1462 + + + + M, F Inhibit
GSK3α/β S21/S9 + + + + M Inhibit
RAF1 S259 + + + + − Inhibit
PRAS40 T246 + + − + M Inhibit
AS160 S588, T642 + + − − − Inhibit
BAD S99 + + + + − Inhibit
WNK1 T60 + + + − M ?
MDM2 S166, S186 + + + + − Activate
Chk1 S280 + + + + M Inhibit
eNOS S1177 + + + + M Activate
ASK1 S83 + + + + − Inhibit
IKKα T23 + − − − − Activate
p21CIP1 T145 + + + + − Inhibit
p27KIP1 T157 + + + + − Inhibit
Casp9 S196 + − + + − Inhibit
aFor an expanded version of this table see Table S1.
bHuman numbering of sites with strongest evidence of being phosphorylated by Akt in vivo.
cDirect phosphorylation of the given site(s) with purified Akt and full-length substrate in vitro.
dEvidence of Akt-dependent phosphorylation of the given site(s) within cells (− means no published evidence), including: W/L, 
sensitivity to PI3K inhibition using ≤ 100 nM wortmannin (W) and/or ≤ 20 µM LY294002 (L); LOF, loss-of-AKT-function evidence 
using dominant-negative mutants and/or RNAi approaches; GOF, gain-of-Akt-function evidence using overexpression and/or 
constitutively active mutants.
eGenetic evidence in model organisms, including epistasis analyses in Drosophila (F) or C. elegans (W) or loss-of-phosphorylation 
in mouse mutants (M) lacking Akt function.
fFunctional consequence of Akt-mediated phosphorylation.erful mouse models for the confirmation of in vivo Akt 
substrates are a pair of PDK1 knockin mutants gener-
ated by Alessi and colleagues. The first is a knockin of 
a PDK1-PH domain mutant (PKD1-RRR472-474LLL or 
PDK1-PHKI), which cannot bind to PI3K lipid products 
and is defective in the phosphorylation and activa-
tion of Akt isoforms, while maintaining the ability to 
phosphorylate the other AGC kinases (McManus et 
al., 2004). The phosphorylation of several proposed 
Akt substrates has been confirmed using PDK1-PHKI 
embryonic stem cells, including sites on FOXO1 and 
3, TSC2, GSK3, PRAS40, and WNK1 (McManus et al., 
2004). The other PDK1 knockin mutant is the PDK1-PIF 
pocket mutant (PDK1-L155E), which can activate Akt 
but not the other AGC kinases (Collins et al., 2003). 
Embryonic stem cells expressing this mutant are use-
ful in parallel to critically test in vivo phosphorylation 
sites for Akt specificity. Ultimately, the dependence on 
Akt activity for the phosphorylation of all candidate 
substrates and sites should be verified in such cell 
and mouse models.1264 Cell 129, June 29, 2007 ©2007 Elsevier Inc.Akt Substrates and Functions
A careful search of the literature finds over 100 reported 
nonredundant Akt substrates, of which approximately 
25% do not contain the minimal requirements for an Akt 
site (e.g., R-X-R-X-X-S/T). Furthermore, many of those 
that do contain this motif have not been characterized 
further than in vitro kinase assays. Although we have not 
determined how all of the remaining published candi-
date Akt substrates measure up to the criteria outlined 
above, we have assessed the literature on 18 substrates 
for which there have been multiple independent pub-
lished reports (Tables 1 and S1). Within this survey, we 
have included an analysis of evolutionary conservation 
(Table S1). The degree of conservation of an identified 
Akt phosphorylation site can be indicative of the rele-
vance of the substrate toward the defined cellular func-
tions of Akt. Most thoroughly studied and independently 
confirmed Akt phosphorylation sites are conserved 
amongst the orthologs from all mammals, and a handful 
are conserved down to invertebrate models such as Dro-
sophila or C. elegans (Table S1, Metazoan). Conserva-
tion analysis is particularly important when using animal 
models to determine the role of Akt substrates in human 
disease. For instance, a study using the rat version of 
the protein Par-4/PAWR concluded that this protein is a 
direct target of Akt essential for Akt’s role in cancer cell 
survival (Goswami et al., 2005), but the proposed Akt site 
is not conserved in human, or even mouse, Par-4/PAWR. 
Finally, it should be stated that exclusion from the list 
in Table 1 or the discussion below does not rule out a 
published substrate as being a bona fide Akt target. We 
anxiously await further study on these other candidate 
substrates.
In this section, we focus on the known cellular func-
tions of Akt and the direct downstream targets of Akt 
that are most likely to mediate these functions. This 
discussion illustrates the most challenging aspect 
of characterizing any kinase-substrate pair: defining 
the functional consequences of phosphorylation of a 
specific site or sites on a new substrate. To this end, 
phosphorylation-site mutants (S/T to A) are particu-
larly useful if the substrate has a known function. Such 
a mutant should block the positive or negative effects 
of Akt on the activity of the substrate or a cellular 
process involving the substrate. Although it has been 
done for very few substrates, the generation of phos-
phorylation-site mutant knockin mice is an especially 
powerful approach for determining the physiologi-
cal importance of phosphorylation of a given target 
by Akt (e.g., McManus et al., 2005). Phosphomimetic 
mutants (S/T to D/E) have a more limited usefulness. 
Changing the phospho-acceptor site to an acidic resi-
due might mimic phosphorylation, but not in all cases. 
This is especially true when the Akt phosphorylation 
site creates a 14-3-3 binding motif, which is a common 
mode of regulation (see below), as D and E residues 
are poor substitutes for phospho-S/T in mediating 14-
3-3 binding. One theme that is obvi-
ous from the discussion below is that 
the diverse cellular roles of Akt do not 
fall under a one-substrate-one-func-
tion paradigm; rather, each physi-
ological response downstream of Akt 
appears to be mediated by multiple 
targets (Figure 2). Furthermore, some 
Akt substrates control more than one cellular function, 
and these functions may vary in a cell- and signal-
context-dependent manner.
Cell Survival
Even before the relevant substrates were identified, sev-
eral groups independently demonstrated a critical role for 
Akt in promoting cell survival downstream of growth fac-
tors, oncogenes, and cell stress (reviewed in Marte and 
Downward, 1997). Akt enhances the survival of cells by 
blocking the function of proapoptotic proteins and proc-
esses. Akt negatively regulates the function or expres-
sion of several Bcl-2 homology domain 3 (BH3)-only 
proteins, which exert their proapoptotic effects by bind-
ing to and inactivating prosurvival Bcl-2 family members. 
For instance, Akt directly phosphorylates and inhibits 
the BH3-only protein BAD (Datta et al., 1997; delPeso et 
al., 1997). Survival factors stimulate Akt-mediated phos-
phorylation of BAD on S136, and this creates a binding 
site for 14-3-3 proteins, which triggers release of BAD 
from its target proteins (Datta et al., 2000). The ability to 
phosphorylate S136 on BAD is important for the survival 
effects of Akt on neurons and other cell types (Datta et 
al., 1997, 2002). Akt also inhibits the expression of BH3-
only proteins through effects on transcription factors, 
such as FOXO and p53. Akt phosphorylates FOXO1 on 
T24, S256, and S319, and it phosphorylates FOXO3a and 
FOXO4 on three equivalent sites (reviewed in Tran et al., 
2003). Akt’s phosphorylation of FOXO proteins occurs 
in the nucleus, and, as with BAD, phosphorylated T24 
and S256 are bound by 14-3-3 proteins, which displace 
FOXO transcription factors from target genes and trigger 
their export from the nucleus. Through this mechanism, 
Akt blocks FOXO-mediated transcription of target genes 
that promote apoptosis, cell-cycle arrest, and metabolic 
processes (see below). An important proapoptotic tar-
get of FOXO proteins is the BH3-only protein BIM, which 
Figure 2. Cellular Functions of Ten Akt 
Substrates
Akt-mediated phosphorylation of these pro-
teins leads to their activation (arrows) or inhibi-
tion (blocking arrows). Regulation of these sub-
strates by Akt contributes to activation of the 
various cellular processes shown (i.e., survival, 
growth, proliferation, glucose uptake, metabo-
lism, and angiogenesis). As illustrated by these 
ten targets, a high degree of functional versatil-
ity and overlap exists amongst Akt substrates. 
See text for detailed descriptions of substrates 
and functions.Cell 129, June 29, 2007 ©2007 Elsevier Inc. 1265
stimulates cell death in hematopoietic lineages upon 
cytokine withdrawal (Dijkers et al., 2002). In addition, 
when unphosphorylated and active, FOXO factors can 
induce the expression of the proapoptotic cytokine Fas 
ligand (FasL; Brunet et al., 1999). A third target of Akt 
that promotes survival by inhibiting BH3-only proteins is 
MDM2 (or HDM2 in humans), an E3 ubiquitin ligase that 
triggers p53 degradation. Akt phosphorylates MDM2 
on S166 and S186, and this promotes translocation of 
MDM2 to the nucleus, where it negatively regulates p53 
function (Mayo and Donner, 2001; Zhou et al., 2001b). 
Two transcriptional targets of p53 are the BH3-only pro-
teins Puma and Noxa, which appear to be the essential 
targets in p53-induced apoptosis (Villunger et al., 2003). 
However, the relative importance of downregulation of 
these p53 targets to Akt-mediated cell survival has not 
been thoroughly examined.
The importance of other direct targets of Akt toward 
inhibiting apoptosis is less well understood. Akt phos-
phorylates GSK3 isoforms on a highly conserved N-
terminal regulatory site (GSK3α-S21, GSK3β-S9), and 
this phosphorylation inactivates the kinase (Cross et 
al., 1995). Although GSK3 has many substrates that 
could explain a proapoptotic role for this Ser/Thr kinase 
(reviewed in Frame and Cohen, 2001), the prosurvival 
Bcl-2 family member MCL-1 has recently been found 
to be a direct target inhibited by GSK3 (Maurer et al., 
2006). Downstream of the Bcl-2 family members within 
the mitochondrial pathway of apoptosis are a cascade of 
caspase-family proteases initiated by caspase-9. Cas-
pase-9 is proteolytically processed and activated from 
its procaspase form upon cytochrome c release from 
the mitochondria. Therefore, Akt activation prevents the 
processing of procaspase-9 through the effects on Bcl-
2 family members described above. Akt has also been 
found to directly phosphorylate S196 on human pro-
caspase-9, and this phosphorylation correlates with a 
decrease in the protease activity of caspase-9 in vitro 
(Cardone et al., 1998). A procaspase-9-S196A mutant 
is more efficient than wild-type caspase-9 at inducing 
apoptosis when co-overexpressed with activated Akt, 
suggesting a role for caspase-9 phosphorylation in the 
antiapoptotic effects of Akt. However, the sequence sur-
rounding caspase-9-S196 is unusual for an Akt substrate 
in that the +1 position is a P, and such proline-directed 
sites are strongly selected against by Akt in peptide 
phosphorylation experiments (Alessi et al., 1996b; Hutti 
et al., 2004). Furthermore, despite the highly conserved 
role of Akt in blocking apoptosis, this Akt phosphoryla-
tion site is not found in all mammals and appears to be 
restricted to caspase-9 in primates. Additional studies 
are required to determine the physiological relevance of 
caspase-9 relative to other proapoptotic proteins inhib-
ited by Akt.
It is also possible that Akt exerts some of its cell-sur-
vival effects through crosstalk with other pathways or 
through effects on nutrient uptake and metabolism. For 
instance, it has been reported that, under some con-1266 Cell 129, June 29, 2007 ©2007 Elsevier Inc.ditions, the PI3K-Akt pathway activates NFκB survival 
signaling or inhibits JNK/p38 apoptotic signaling (e.g., 
Kim et al., 2001; Ozes et al., 1999; Romashkova and 
Makarov, 1999). An important, but more indirect, effect 
of Akt signaling on cell survival is through its roles in 
nutrient uptake, metabolism, and the maintenance of 
mitochondrial membrane potential (reviewed in Plas and 
Thompson, 2005; Robey and Hay, 2006). Both signaling 
crosstalk and effects of Akt on cellular metabolism are 
discussed in detail below.
Cell Growth
One of the best-conserved functions of Akt is its role in 
promoting cell growth (i.e., an increase in cell mass). The 
predominant mechanism appears to be through activa-
tion of mTOR complex 1 (mTORC1 or the mTOR-rap-
tor complex), which is regulated by both nutrients and 
growth factor signaling. MTORC1 is a critical regulator of 
translation initiation and ribosome biogenesis and plays 
an evolutionarily conserved role in cell growth control 
(reviewed in Wullschleger et al., 2006). The enhanced 
sensitivity of cancer cells and mouse tumor models 
exhibiting oncogenic activation of the PI3K-Akt pathway 
to mTORC1 inhibitors, such as rapamycin, illustrates the 
importance of mTORC1 activation downstream of Akt 
(reviewed in Sabatini, 2006). Although Akt activation 
has been known for some time to effect downstream 
substrates of mTORC1, such as S6K1 and eukaryotic 
initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1), 
the mechanism by which Akt regulates mTORC1 signal-
ing to these targets was more difficult to ascertain. Akt 
has been suggested to directly phosphorylate mTOR on 
S2448, which often correlates with mTORC1 activation, 
but mutational analysis has failed to demonstrate any 
functional significance for this phosphorylation (Scott 
et al., 1998; Sekulic et al., 2000). Moreover, S6K1 rather 
than Akt has recently been shown to be responsible for 
phosphorylation of this site (Chiang and Abraham, 2005; 
Holz and Blenis, 2005).
Complementary approaches by several independent 
laboratories using Drosophila genetics and mammalian 
cell biology found that the tuberous sclerosis complex 
2 (TSC2; also known as tuberin) tumor suppressor is 
a critical negative regulator of mTORC1 signaling (Gao 
and Pan, 2001; Goncharova et al., 2002; Tapon et al., 
2001) and that Akt-mediated phosphorylation inhibits 
TSC2 function (Inoki et al., 2002; Manning et al., 2002; 
Potter et al., 2002). Akt has been shown to directly 
phosphorylate two sites on TSC2 (S939 and T1462 on 
the full-length human protein), which are conserved 
and phosphorylated in Drosophila TSC2, and is likely to 
phosphorylate two or three additional sites (S981 and 
S1130/S1132). The relative importance of these distinct 
sites for Akt’s regulation of TSC2 downstream of differ-
ent stimuli has yet to be determined. However, various 
phosphorylation-site mutants (S/T to A) of TSC2 can 
dominantly block Akt-mediated activation of mTORC1 
signaling (Cai et al., 2006; Inoki et al., 2002; Manning et 
al., 2002). TSC2, in a complex with its binding partner 
TSC1 (also known as hamartin), acts as a GTPase-acti-
vating protein (GAP) for the Ras-related small G protein 
Rheb, which strongly activates mTORC1 when in its 
GTP-bound active form (Figure 1; reviewed in Manning 
and Cantley, 2003). Therefore, Akt activates mTORC1 
indirectly by inhibiting TSC2, thereby allowing Rheb-
GTP to activate mTORC1 signaling.
More recently, a second Akt substrate has been found 
to be involved in mTORC1 regulation. Like TSC2 (Man-
ning et al., 2002), the proline-rich Akt substrate of 40 kDa 
(PRAS40) was identified using the Akt phospho-substrate 
antibody and was found to be a major protein bound to 
14-3-3 in response to insulin (Kovacina et al., 2003). 
PRAS40 was independently identified (dubbed p39) 
for its ability to bind to 14-3-3 proteins in a growth-fac-
tor- and nutrient-regulated manner (Harthill et al., 2002). 
Although the function of the protein was unknown, Akt 
was shown to directly phosphorylate PRAS40 on T246 
(Kovacina et al., 2003), and this phosphorylation was 
later shown to be important for 14-3-3 binding (Vander 
Haar et al., 2007). It should be noted that T246 has the 
minimal requirements for an Akt phosphorylation site, yet 
it scores significantly low relative to other Akt substrates 
(Table S1), suggesting that additional kinases might also 
phosphorylate this site. Importantly, PRAS40 has been 
found to associate with mTORC1 and appears to nega-
tively regulate mTORC1 signaling (Sancak et al., 2007; 
Vander Haar et al., 2007). Overexpression of a PRAS40-
T246A mutant can block Akt activation of S6K1, sug-
gesting that Akt-mediated phoshorylation of PRAS40 at 
T246 stimulates mTORC1 signaling. In addition, there is 
a weak homolog of PRAS40 in Drosophila called Lobe, 
which contains a site with similarity to T246, and Lobe 
appears to behave like PRAS40 in Drosophila S2 cells 
(Sancak et al., 2007). A requirement for Lobe phosphor-
ylation in parallel to TSC2 phosphorylation might explain 
the lack of an obvious developmental phenotype in Dro-
sophila expressing an Akt phosphorylation-site mutant 
of TSC2 (Dong and Pan, 2004). Therefore, there appears 
to be two parallel and, perhaps, functionally redundant 
mechanisms by which Akt activates mTORC1 (Figure 1). 
It will be interesting to determine the relative importance 
of TSC2 and PRAS40 for Akt-mediated mTORC1 activa-
tion under different physiological conditions.
Aside from the ability of mTORC1 to enhance protein 
synthesis through its downstream targets, additional 
anabolic processes through which Akt stimulates an 
increase in cell size are poorly defined. Both mTORC1-
dependent and -independent functions of Akt in nutri-
ent uptake and metabolism are likely to contribute to 
increases in cell growth (e.g., Edinger and Thompson, 
2002; Plas and Thompson, 2005). In addition to increas-
ing protein content, in order for a cell to gain size it must 
increase membrane biosynthesis. One suggested target 
of Akt that would contribute to the synthesis on new 
lipids is ATP citrate lyase (ACL; Berwick et al., 2002), 
which converts citrate to cytosolic acetyl CoA thereby 
providing the essential building block for lipid biosyn-thesis. However, the proposed Akt phosphorylation site 
on ACL (S454; P-S-R-T-A-S-F) lacks the critical −5 R. It 
will be important to examine the phosphorylation of this 
site in the Akt loss-of-function mouse models described 
above.
Cell Proliferation
Although Akt is best known for promoting cell survival 
and growth through pathways parallel to Erk’s control 
over cell proliferation, Akt activation can also stimu-
late proliferation through multiple downstream targets 
impinging on cell-cycle regulation. Several groups have 
independently found that Akt phosphorylates the p27Kip1 
cyclin-dependent kinase inhibitor on T157 (Liang et al., 
2002; Shin et al., 2002; Viglietto et al., 2002), and this 
leads to cytosolic sequestration via 14-3-3 binding 
(Sekimoto et al., 2004). Preventing p27 localization to 
the nucleus attenuates its cell-cycle inhibitory effects. 
Expression of a phosphorylation-site mutant of p27 (p27-
T157A) blocks the proliferative effects of various consti-
tutively active Akt derivatives (Liang et al., 2002; Shin et 
al., 2002; Viglietto et al., 2002). However, Akt-mediated 
phosphorylation of p27 is not required for its effects on 
proliferation in all systems, as T157 is not conserved in 
rodent versions of p27. Akt also inhibits p27 expression 
through phosphorylation and inhibition of the FOXO 
transcription factors (Medema et al., 2000). Akt has 
also been found to phosphorylate the cyclin-dependent 
kinase inhibitor p21Cip1/WAF1 on T145, which is a low-scor-
ing Akt site on Scansite, and, like p27, this phosphor-
ylation leads to p21 cytosolic localization (Zhou et al., 
2001a). Interestingly, it has been suggested that Akt1, 
but not Akt2, phosphorylates and inhibits p21, whereas 
Akt2 appears to bind and stabilize p21, thereby blocking 
cell-cycle progression (Heron-Milhavet et al., 2006). Akt 
might also inhibit p21 expression through its phosphor-
ylation and activation of MDM2 and subsequent down-
regulation of p53-mediated transcription of p21 (Mayo 
and Donner, 2001; Zhou et al., 2001b).
Akt-dependent phosphorylation of targets already 
discussed, such as GSK3, TSC2, and PRAS40, is also 
likely to drive cell proliferation through regulation of the 
stability and synthesis of proteins involved in cell-cycle 
entry. GSK3-mediated phosphorylation of the G1 cyclins 
cyclin D and cyclin E and the transcripton factors c-jun 
and c-myc, which all play a central role in the G1-to-S-
phase cell-cycle transition, targets them for proteasomal 
degradation (Diehl et al., 1998; Wei et al., 2005; Welcker 
et al., 2003; Yeh et al., 2004). Therefore, phosphoryla-
tion and inhibition of GSK3 by Akt should enhance the 
stability of these proteins. Akt signaling also controls the 
translation of proteins important for cell-cycle progres-
sion, predominantly through phosphorylation of TSC2 
and PRAS40 and subsequent activation of mTORC1. 
Although best known for its role in promoting cell growth, 
mTORC1 is a critical regulator of cell proliferation. The 
predominant cellular effect of mTORC1 inhibitors, such 
as rapamycin, is to cause a G1 cell-cycle arrest, and Akt-
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has recently been shown to be dependent on mTORC1 
activation (Skeen et al., 2006). Akt signaling leads to 
activation of eIF4E through mTORC1’s inhibition of 4E-
BP1, and eIF4E promotes the cap-dependent transla-
tion of many target mRNAs, including those encoding 
cyclin D1 and c-Myc (reviewed in Mamane et al., 2004). 
Therefore, as with cell survival and growth, Akt controls 
cell proliferation through multiple complementary down-
stream pathways.
Whether PI3K-Akt signaling is important in the transi-
tion through other phases of the cell cycle is less clear. 
In some cell lines, Akt activity has been shown to be ele-
vated during the G2/M phase of the cell cycle, and Akt 
activation promotes progression through mitosis, even 
in the presence of DNA damage (Kandel et al., 2002; 
Shtivelman et al., 2002). One mechanism explaining this 
observation is that Akt directly phosphorylates the DNA 
damage checkpoint kinase Chk1 on S280 (King et al., 
2004; Puc et al., 2005). S280 phosphorylation blocks 
checkpoint function by stimulating Chk1 translocation to 
the cytosol, where it is sequestered from the DNA dam-
age-sensing kinases ATM and ATR (Puc et al., 2005). 
Therefore, loss of the PTEN tumor suppressor causes a 
checkpoint defect due to constitutive Akt activation and 
phosphorylation of Chk1, and this might contribute to 
genomic instability in this setting.
Angiogenesis
Akt plays important roles in both physiological and path-
ological angiogenesis through effects in both endothe-
lial cells and cells producing angiogenic signals, such as 
tumor cells. In endothelial cells, the PI3K-Akt pathway is 
robustly activated by vascular endothelial growth factor 
(VEGF; reviewed in Olsson et al., 2006), and phospho-
rylation of the Akt targets discussed above is likely to 
contribute to endothelial cell survival, growth, and prolif-
eration. In addition, Akt activates endothelial nitric oxide 
(NO) synthase (eNOS) through direct phosphorylation of 
S1177 (Dimmeler et al., 1999; Fulton et al., 1999). The 
release of NO produced by activated eNOS can stimu-
late vasodilation, vascular remodeling, and angiogen-
esis (reviewed in Morbidelli et al., 2003). Akt signaling 
also leads to an increased production of the hypoxia-
inducible factor α (HIF1α and HIF2α) transcription fac-
tors, at least in part, through mTORC1-dependent trans-
lation (reviewed in Gordan and Simon, 2007; Semenza, 
2003). HIFα activation in endothelial cells and other cells 
leads to expression and subsequent secretion of VEGF 
and other angiogenic factors, thereby stimulating ang-
iogenesis through both autocrine and paracrine signal-
ing. Finally, Akt1, the primary isoform in endothelial cells, 
is required for proper endothelial cell migration (Ackah 
et al., 2005), although the relevant downstream targets 
have not been defined.
Cellular Metabolism
In response to growth factors, Akt signaling regulates 
nutrient uptake and metabolism in a cell-intrinsic and 
cell-type-specfic manner through a variety of down-
stream targets. One of the most important physiologi-1268 Cell 129, June 29, 2007 ©2007 Elsevier Inc.cal functions of Akt is to acutely stimulate glucose 
uptake in response to insulin. Akt2, the primary iso-
form in insulin-responsive tissues, has been found to 
associate with glucose transporter 4 (Glut4)-contain-
ing vesicles upon insulin stimulation of adipocytes 
(Calera et al., 1998), and Akt activation leads to Glut4 
translocation to the plasma membrane (Kohn et al., 
1996). Although the precise molecular mechanisms 
by which Akt stimulates Glut4 translocation are still 
being intensely studied, the Rab-GAP AS160 (also 
known as TBC1 domain family member 4; TBC1D4) 
has emerged as an important direct target of Akt 
involved in this process (Eguez et al., 2005; Sano et 
al., 2003). Five putative Akt sites are phosphorylated 
on AS160 in response to insulin, of which S588 and 
T642 score the highest using the Scansite program. 
Importantly, mutation of these two sites to alanine 
significantly blocks insulin-stimulated Glut4 translo-
cation (Sano et al., 2003). The current model is that 
Akt-mediated phosphorylation of some combination 
of the sites on AS160 inhibits its GAP activity, thereby 
allowing a Rab-family GTPase to become GTP loaded 
and stimulate Glut4 vesicle translocation. However, 
recent studies have suggested AS160-independent 
mechanisms of regulation of this process (Bai et al., 
2007), and other candidate Akt substrates involved in 
various steps of Glut4 translocation have been iden-
tified, including PIKfyve (Berwick et al., 2004). Glut1 
is the main glucose transporter in most cell types, 
and unlike Glut4, it appears to be regulated primarily 
through alterations in expression levels. Activation 
of mTORC1, through Akt-mediated phosphorylation 
of TSC2 and PRAS40, can contribute to both HIFα-
dependent transcription of the Glut1 gene and cap-
dependent translation of Glut1 mRNA (e.g., Taha et 
al., 1999; Zelzer et al., 1998). The frequent occurrence 
of PI3K-Akt pathway activation and HIFα accumula-
tion in human cancers is likely to explain the high lev-
els of Glut1 and enhanced glucose uptake observed 
in tumors (reviewed in Majumder and Sellers, 2005; 
Semenza, 2003). In addition to glucose uptake, Akt 
has also been suggested to regulate the cell surface 
expression of transporters for other nutrients, such 
as amino acids, in an mTORC1-dependent manner 
(Edinger and Thompson, 2002). However, the mecha-
nism and broader applicability of this effect of Akt and 
mTORC1 are currently unclear.
Akt activation can also alter glucose and lipid 
metabolism within cells. Upon entry into the cell, glu-
cose is converted to its active form glucose 6-phos-
phate through the action of hexokinases. Akt has been 
demonstrated to stimulate the association of hexoki-
nase isoforms with the mitochondria, where they more 
readily phosphorylate glucose, but the direct target 
of Akt responsible is currently unknown (reviewed 
in Robey and Hay, 2006). Glucose 6-phosphate can 
be stored by conversion to glycogen or catabolized 
to produce cellular energy through glycolysis, and 
Akt signaling can regulate both of these processes. 
Particularly important in muscle and liver, Akt-medi-
ated phosphorylation and inhibition of GSK3 prevents 
GSK3 from phosphorylating and inhibiting its name-
sake substrate glycogen synthase, thereby stimulat-
ing glycogen synthesis. Akt activation also increases 
the rate of glycolysis (Elstrom et al., 2004), and this is 
probably a major factor contributing to the highly gly-
colytic nature of tumor cells. Akt’s ability to enhance 
the rate of glycolysis is due, at least in part, to its abil-
ity to promote the expression of glycolytic enzymes 
through HIFα (e.g., Lum et al., 2007; Majumder et al., 
2004; Semenza et al., 1994). In a cell-context-depend-
ent manner, Akt-mediated phosphorylation and inhibi-
tion of FOXO1 also contribute to glucose homeostasis, 
as FOXO1 promotes hepatic glucose production and 
regulates the differentiation of cells involved in meta-
bolic control (reviewed in Accili and Arden, 2004). In 
hepatocytes, Akt can also inhibit gluconeogenesis and 
fatty acid oxidation through direct phosphorylation of 
S570 on PGC-1α (Li et al., 2007), which is a coactiva-
tor that can coregulate genes with FOXO1 and other 
transcription factors. Akt signaling regulates lipid 
metabolism through phosphorylation and inhibition of 
GSK3. As described above, phosphorylation of sub-
strates by GSK3 often targets them for proteasomal 
degradation, and GSK3 has been shown to promote 
degradation of the sterol regulatory element-bind-
ing proteins (SREBPs), which are transcription fac-
tors that turn on the expression of genes involved in 
cholesterol and fatty acid biosynthesis (Sundqvist et 
al., 2005). Therefore, Akt-mediated inhibition of GSK3 
promotes SREBP stability and enhances lipid produc-
tion. As discussed above, Akt has also been proposed 
to directly activate ACL (Berwick et al., 2002), with the 
caveat that the relevant phosphorylation site on this 
enzyme does not meet the minimal consensus for an 
Akt site. As intense interest in the role of the PI3K-Akt 
pathway in metabolic diseases and tumor metabolism 
continues, it is likely that Akt signaling will be found to 
impinge on many other areas of central metabolism.
Cell Migration and Invasion
Until recently, a role for Akt in the control of cell migra-
tion, invasion of the extracellular matrix, and ultimately 
metastasis has been difficult to ascertain. Strikingly, 
activation of Akt1 has been found to decrease mam-
mary epithelial cell migration, and Akt1 prevents an epi-
thelial-to-mesenchymal transition that resembles events 
required for metastasis (Irie et al., 2005; Yoeli-Lerner et 
al., 2005). Two independent mechanisms for this surpris-
ing Akt function have been explored. The first found that 
the inhibitory effect of Akt1 on the in vitro migration and 
invasion properties of breast cancer cell lines involved 
a pathway leading to degradation of the nuclear factor 
of activated T cells (NFAT) transcription factors (Yoeli-
Lerner et al., 2005). However, the molecular mecha-
nism of Akt1-mediated degradation of NFAT is currently 
unknown. A second group found that siRNA knockdown of Akt1, but not Akt2, led to an increase in the migra-
tion of mammary epithelial cells (Irie et al., 2005). Loss 
of Akt1, specifically, led to an increase in the activa-
tion of Erk1 and Erk2, which was found to be required 
for the enhanced migration. Again, the mechanism by 
which Akt1, but not Akt2, inhibits Erk signaling in this 
system remains unknown. Interestingly, mouse tumor 
models have also suggested that Akt1 inhibits metas-
tases (Hutchinson et al., 2004), whereas Akt2 promotes 
metastases (Arboleda et al., 2003). However, these 
differential effects of Akt1 and Akt2 on epithelial cell 
migration may not translate to other cell types. In fact, 
studies on cell migration using mouse embryonic fibrob-
lasts deficient of specific Akt isoforms have suggested 
opposite effects on fibroblast migration, with Akt1 pro-
moting migration and with Akt2 inhibiting it (Zhou et al., 
2006). These studies demonstrate both the importance 
of crosstalk between the PI3K-Akt pathway and other 
pathways and the emerging recognition that the three 
isoforms of Akt can have distinct cellular functions.
Crosstalk with Other Pathways
Extensive research on the wiring of signal transduction 
pathways over the past ten years has uncovered a level 
of complexity dictating that no single pathway operates 
in isolation and that pathways are small parts of fully inte-
grated networks within the cell. This is certainly true of the 
PI3K-Akt pathway, and we discuss just three examples 
here. Several studies have demonstrated that Akt sign-
aling can activate the NF-κB transcription factor down-
stream of a variety of stimuli, such as tumor necrosis 
factor (TNFα), and platelet-derived growth factor (PDGF; 
e.g., Ozes et al., 1999; Romashkova and Makarov, 1999). 
Although there are likely to be multiple levels of crosstalk 
between the PI3K-Akt and NF-κB pathways, one mecha-
nism has been attributed to direct phosphorylation of the 
amino acid residue T23 on IκB kinase α (IKKα) by Akt, 
thereby leading to activation of this kinase upstream of 
NF-κB (Ozes et al., 1999). However, to date this connec-
tion between Akt and IKKα has not been verified conclu-
sively in vivo. Akt also blocks Erk signaling through inhi-
bition of c-Raf (Raf1; Rommel et al., 1999; Zimmermann 
and Moelling, 1999). Akt can directly phosphorylate c-Raf 
on T259, and this can lead to an inhibitory effect of Akt 
on the Erk pathway (Zimmermann and Moelling, 1999). As 
with NF-κB, this crosstalk between Akt and Erk signaling 
is not ubiquitous and appears to occur only in specific 
settings. In addition to Erk, the stress-activated MAPKs 
JNK and p38 have also been shown to be inhibited by 
Akt signaling. Akt can directly phosphorylate the amino 
acid residue S83 on apoptosis signal-regulated kinase 1 
(ASK1, also known as MAPKKK5), which is an upstream 
activating kinase within the JNK and p38 pathways (Kim 
et al., 2001). Akt blocks the apoptotic stimulus-induced 
activation of ASK1 in a manner dependent on S83. There-
fore, a balance between PI3K-Akt survival signaling and 
JNK/p38 apoptotic signaling can be established through 
such crosstalk.Cell 129, June 29, 2007 ©2007 Elsevier Inc. 1269
Substrate Selectivity between Akt Isoforms and 
Other AGC Kinases
From the discussion above, it should be obvious that 
Akt phosphorylates lots of different targets involved in a 
large variety of cellular processes and that it is unlikely 
that Akt hits all of these targets in every setting. Aside 
from differences in substrate expression under various 
conditions, Akt is also likely to have stimulus-specific 
differences in its substrate utilization. Although there are 
many possible explanations, including temporal consid-
erations, subcellular localization, and degree of kinase 
activation, the mechanisms dictating substrate selectiv-
ity are poorly understood. Recent observations using 
mouse embryonic fibroblasts lacking components of 
the Akt-activating kinase mTORC2 have suggested that 
phosphorylation of Akt at S473 is required for its ability to 
properly phosphorylate the N-terminal site on the FOXO 
proteins, but phosphorylation of Akt-S473 does not 
appear to be required for Akt-mediated phosphorylation 
of the other FOXO sites or the sites on TSC2 and GSK3 
(Guertin et al., 2006; Jacinto et al., 2006). Therefore, it 
has been argued that S473 phosphorylation can dictate 
differential substrate utilization (Jacinto et al., 2006). 
Another viable explanation is that different substrates, 
and even different sites on a single substrate, require 
different levels of Akt activity to reach saturation or to be 
phosphorylated to an extent that we can detect experi-
mentally (i.e., using available phospho-specific antibod-
ies). To this end, it is has been known for some time that 
S473 phoshorylation is not essential for growth-factor 
stimulation of Akt, but it does result in a 5- to 10-fold 
increase in Akt activity (Alessi et al., 1996a). However, 
to our knowledge, there are no physiological stimuli that 
result in T308 phosphorylation in the absence of S473 
phosphorylation. Although it is an intriguing possibility, 
further work is clearly required to support a model in 
which S473 dictates a substrate-switching mechanism.
An exciting area of Akt research is the increasing 
number of studies demonstrating isoform-specific func-
tions for Akt. The three Akt isoforms are very similar, 
especially within their kinase domains, and it is unlikely 
that they have distinguishable substrate specificities in 
vitro. Furthermore, Akt1 and Akt2 are expressed ubiq-
uitously, and many cell lines express all three isoforms. 
However, mouse knockouts have uncovered distinct 
physiological functions for the three Akt isoforms: Akt1-
deficient mice display developmental defects, Akt2-defi-
cient mice have defects in glucose homeostasis, and 
Akt3-deficient mice show defects in brain development 
(reviewed in Dummler and Hemmings, 2007). Although 
combined knockouts have illustrated that functional 
redundancy exists between the three isoforms, the dis-
tinct phenotypes resulting from loss of each individually 
suggests that there are likely to be functional differences 
at the cellular level. The first clear example of this was 
the role of Akt in stimulating Glut4 translocation in adi-
pocytes, where it was found that Akt2 rather than Akt1 
was the primary isoform responsible (e.g., Katome et al., 1270 Cell 129, June 29, 2007 ©2007 Elsevier Inc.2003). A second example is the one discussed above 
regarding the differential effects of Akt1 and Akt2 on 
cell migration (Irie et al., 2005; Zhou et al., 2006). In both 
instances, there must be an isoform-specific substrate 
to which the other isoforms have less access or ability 
to recognize. A recent study on the role of two Akt-S473 
phosphatases, PHLPP1 and PHLPP2, which differen-
tially regulate the three Akt isoforms, has emphasized 
the extent to which Akt substrates are isoform specific 
(Brognard et al., 2007). A survey of the phosphorylation 
status of six known Akt substrates following siRNA-medi-
ated knockdown of each of the three Akt isoforms beau-
tifully demonstrated that each isoform has both unique 
and overlapping substrate specificities. More work is 
required to determine if the specificities observed per-
tain to all cell lines and, most importantly, what dictates 
this specificity.
A further complicating factor in the study of Akt sig-
naling is that other AGC family members can, in certain 
settings, phosphorylate sites previously characterized 
to be bona fide Akt targets. This often occurs in situ-
ations where a stimulus or genetic lesion strongly acti-
vates an AGC kinase in the absence of Akt activation. For 
instance, S6K1 can phosphorylate GSK3 on its Akt site 
under conditions of elevated mTORC1-S6K1 signaling, 
which triggers a negative feedback mechanism block-
ing growth-factor activation of Akt (Zhang et al., 2006). 
However, other AGC kinases can also be redundant with 
Akt under circumstances where Akt remains active and 
capable of phosphorylating a specific site. This appears 
to be the case for T32 on FOXO3a, where both Akt and 
the closely related AGC kinase SGK can phosphorylate 
this site in response to PI3K-activating stimuli (Brunet 
et al., 2001). How widespread such compensatory and 
redundant mechanisms are in Akt signaling is not known, 
but the potential for alternative regulation should be kept 
in mind when examining any seemingly well-character-
ized target in a novel setting.
The Future of Akt Research
Incredible insight into the regulation and function of Akt 
has been gained over the past ten years. However, the 
clear recognition that defects in Akt signaling underlie 
a diverse array of human diseases makes the clarifi-
cation of downstream targets and functions of cen-
tral importance to our understanding and treatment of 
such diseases. As our ability to knockout, knockdown, 
or pharmacologically inhibit specific Akt isoforms and 
related AGC kinases has significantly improved, previ-
ously identified substrates should be more rigorously 
confirmed. More advanced animal models, such as 
knockins encoding catalytically inactive mutants of the 
three Akt isoforms—which should be less susceptible to 
functional compensation than complete knockouts—will 
likely provide a more accurate picture of isoform-spe-
cific substrates and functions. Knockin mutants encod-
ing substrates lacking Akt phosphorylation sites will 
allow a critical determination of the in vivo relevance and 
contribution of defined phosphorylation events to spe-
cific physiological and pathological states. With respect 
to determinants of Akt substrate specificity within cells, 
many difficult questions remain. How do the three Akt 
isoforms differ in their regulation, localization, and sub-
strate utilization? What is the degree of functional redun-
dancy between the Akt isoforms and other AGC kinases? 
Which substrates are subjected to such redundancy, 
and how is this dictated? Do Akt isoforms use dock-
ing sites separate from phosphorylation sites to recog-
nize substrates? How do different Akt-activating stimuli 
impinge on substrate selectivity? It will also be important 
to further define the role of crosstalk between distinct 
downstream branches of the PI3K-Akt pathway, as well 
as with other signaling pathways, in the ultimate physio-
logical outcome of Akt activation. Our ability to grasp the 
complex circuitry of Akt signaling and to predict the con-
sequences of altering specific components of the larger 
network will require systems biological approaches as a 
complement to genetics and biochemistry. Although the 
past ten years have been spent assembling a parts list, 
the challenging work of piecing it all together and figur-
ing out how it really works lies ahead.
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